002774 |
Q. Li [Australie] ; J. Chalmers [Australie] ; S. Czernichow [Australie, France] ; B. Neal [Australie] ; B. A. Taylor [Norvège] ; S. Zoungas [Australie] ; N. Poulter [Royaume-Uni] ; M. Woodward [Australie, États-Unis] ; A. Patel [Australie] ; B. De Galan [Australie, Pays-Bas] ; G. D. Batty [Australie, Royaume-Uni] | Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial |